

SEED

Intellectual Property Law Group PLLC

701 Fifth Avenue, Suite 6300
Seattle WA 98104-7092 USA
Facsimile: (206) 682-6031
Telephone: (206) 622-4900
www.seedlaw.com

FAX RECEIVED

APR 10 2002

April 9, 2002

GROUP 1600

Julie A. Urvater, Ph.D.
julieu@seedlaw.com

Facsimile Transmission2 pages including this page**TO: Examiner Ron Schwadron**

Fax No.: 703-308-4242

Phone No.: 703-308-4680

RE: Corrected Response of 10/23/01


Your Reference: 09/164,223

Our Reference: 210121.465

☐ Urgent ☐ For Review ☐ Please Confirm Receipt ☐ Please Reply ASAP

Comments:

Dear Examiner Schwadron: Per our telephone conversation yesterday, April 8, 2002, attached is the requested corrected page of the Version with Markings to Show Changes Made from our Response of 10/23/01. Please let me know if you require anything further. Thank you.



If you do not receive all pages, please call Judy Davies at (206) 622-4900 or fax our office.

Transmission Information: Date _____ Time _____ By _____

CONFIDENTIALITY NOTICE: The information contained in this facsimile message is legally privileged and/or confidential information intended only for the use of the addressee named above. If you are not the intended recipient, you are hereby notified that any use, dissemination, distribution, or copying of this facsimile or its content is strictly prohibited. If you have received this facsimile in error, please immediately notify us by telephone and return the original facsimile message to us by mail or destroy it without making a copy. Thank you.

react with WT1-specific antisera and/or T-cell lines or clones is not substantially diminished, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2 or 3.

107. (Amended) ~~A pharmaceutical composition comprising a polypeptide an immunogenic portion of native WT1 according to claim 104, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2~~ in combination with a pharmaceutically acceptable carrier or excipient.

108. (Amended) ~~An immunogenic composition comprising a polypeptide an immunogenic portion of native WT1, wherein the immunogenic portion consists of the contiguous amino acids of SEQ ID NO:2 according to claim 104,~~ in combination with a non-specific immune response enhancer.

109. (Amended) ~~A immunogenic composition according to claim 108,~~ wherein the immune response enhancer is an adjuvant.

110. (Amended) ~~A immunogenic composition comprising:~~

(a) ~~a WT1 polypeptide, wherein the polypeptide comprises consisting of an immunogenic portion of a native WT1 or a variant thereof that differs from the immunogenic portion due to substitutions at between 1 and 3 amino acid positions within the immunogenic portion, in one or more substitutions, deletions, additions and/or insertions such that the ability of the variant to react with antigen-specific T cell lines or clones is not substantially diminished;~~ and

(b) a non-specific immune response enhancer that preferentially enhances a T cell response in a patient;

wherein said ~~WT1 polypeptide immunogenic portion comprises~~ consists of the contiguous amino acids of SEQ ID NO:2 or 3.

111. (Amended) ~~A immunogenic composition according to claim 110,~~ wherein the immune response enhancer is selected from the group consisting of Montanide